Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 8, 2012, Pages 1043-1050

  Lionetto, Luana ^a   Casolla, Barbara ^a   Mastropietri, Fabiola ^a   D'Alonzo, Lidia ^b   Negro, Andrea ^b,c   Simmaco, Maurizio ^a   Martelletti, Paolo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cluster hedache; Menstrual related migraine; Migraine; Pharmacodynamics; Pharmacokinetics; Triptans; Zolmitriptan

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMITRIPTYLINE; ATENOLOL; DOPAMINE RECEPTOR; ELETRIPTAN; FROVATRIPTAN; HISTAMINE RECEPTOR; METOPROLOL; MONOAMINE OXIDASE INHIBITOR; NADOLOL; NARATRIPTAN; PLACEBO; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TIMOLOL; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZOLMITRIPTAN;

ACUTE CORONARY SYNDROME; ARTICLE; BINDING AFFINITY; BRAIN BLOOD VESSEL; CARDIOVASCULAR RISK; CLUSTER HEADACHE; COMPETITIVE INHIBITION; CORRELATION ANALYSIS; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; HYPERTENSION; MEDLINE; MENSTRUAL MIGRAINE; MIGRAINE; NAUSEA; NAUSEA AND VOMITING; PAIN ASSESSMENT; PARESTHESIA; PHARMACODYNAMICS; PHARYNGITIS; PHONOPHOBIA; PHOTOPHOBIA; SEX DIFFERENCE; SOMNOLENCE; SORE THROAT; SYSTEMATIC REVIEW; TABLET DISINTEGRATION; VISUAL ANALOG SCALE;

CLUSTER HEADACHE; DRUG EVALUATION; HUMANS; MIGRAINE DISORDERS; OXAZOLIDINONES; TREATMENT OUTCOME; TRYPTAMINES;

EID: 84864046914     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.701618     Document Type: Article

References (52)

1. Tepper J, Stillman J. What is the best drug-delivery approach for the acute treatment of migraine? Expert Rev. Neurother 2012;12(3):253-255
2. Matchar DB, Young WB. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Copyright -by the American Academy of Neurology: LICENSED to the members of the US Headache Consortium.
3. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002;59(7):1084-1088
4. Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 2008;9(1):5-12
5. Hamel E. Serotonin and migraine: Biology and clinical implications. Cephalalgia 2007;27:1295-1300
6. Glen RC, Martin GR, Hill AP, et al. Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compound with potential antimigraine properties. J Med Chem 1995;38(18):3566-3580
7. Martin GR, Robertson AD, MacLennan SJ, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (Zolmitriptan). Br J Pharmacol 1997;121(2):157-164
8. Shepheard SL, Williamson DJ, Cook DA, et al. Preclinical comparative studies on the sympatholytic effects of 5-HT1D receptor agonists in vivo. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment. Trial methodology and new trials. Lippincot-Raven; PA, USA: 1997. p. 293-302
9. De Hoon JNJM, Willgers JM, Troost J, et al. Vascular effects of 5HT1B/1Dreceptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000;68:418-426
10. Humphrey PPA, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989;9(Suppl 9):23-33
11. Dixon R, Gillotin C, Gibbens M, et al. The pharmacokinetics and effects on blood pressure of multiple doses of the novel antimigraine drug zolmitriptan. (311C90) in healthy volunteers. Br J Clin Pharmacol 1997;43(3):273-281
12. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-187
13. Martin GR. Pre-clinical pharmacology of zolmitriptan (Zomig-); formerly 311C90), a centrally and peripherally acting5-HT1B/1D agonist for migraine. Cephalalgia 1997;17(Suppl 18):4-14
14. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311
15. Smith DA, Cleary EW, Watkins S, et al. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: A double-blind, placebo-controlled study. J Clin Pharmacol 1998;38(8):685-693
16. Humphrey PPA, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate Cephalalgia 1994;14:401-1025
17. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in cat. Cephalalgia 1997;17:153-158
18. Hoskin KL, Knight YE, Goadsby PJ. Zolmitriptan inhibits c-fos expression in the dorsal horn of the medulla and upper cervical horn evoked by sagittal sinus stimulation in the cat [abstract]. Cephalalgia 1996;16:355
19. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010;70(12):1505-1518
20. Goadsby PJ, Yates R. Zolmitriptan intranasal: A review of the pharmacokinetics and clinical efficacy. Headache 2006;46(1):138-149
21. Seaber EJ, Peck RW, Smith DA, et al. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br J Clin Pharmacol 1998;46(5):433-439
22. Yates RA, Tateno M, Nairn K, et al. The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects. Eur J Clin Pharmacol 2002;58(4):247-252
23. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43(4):376-388
24. Bigal ME, Bordini CA, Antoniazzi AL, et al. The triptan formulations: A critical evaluation. Arq Neuropsiquiatr 2003;61(2A):313-320
25. Zingmark PH, Yates R, Hedlund C, et al. True nasopharyngeal absorption of zolmitriptan following administration of zolmitriptan nasal spray. Eur J Neurol 2003;10(Suppl 1):76
26. Dodick D, Lipton RB, Martin V, et al. Triptan cardiovascular safety expert panel: Consensus statement: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414-425
27. Ottervanger JP, Paalman HJ, Boxma GL, et al. Transmural myocardial infarction with sumatriptan. Lancet 1993;341:861-862
28. Anghileri E, Toso V, Perini F. Acute myocardial infarction after sumatriptan administration for cluster headache. Neurol Sci 2006;26:456-459
29. Weir RA, Oldroyd KG, Walters MR. Myocardial infarction after oral sumatriptan use in a woman with normal coronary arteries. Am J Med 2007;120:7-8
30. Ribeiro H, Batista A, Ferreira C, et al. Myocardial infarction after taking zolmitriptan. Portuguese Journal of Cardiology, Rev Port Cardiol 2012;31(2):167-169
31. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337-1345
32. Seaber E, On N, Dixon RM, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997;43(6):579-587
33. Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev 2010;14(4):CD008042
34. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT IB/ID agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001;358:1668-1675
35. Rapoport AM, Tepper SJ, Bigal ME, et al. The triptans formulations: How to match patients and products. CNS Drugs 2003;17(6):431-447
36. Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003;17(9):653-667
37. Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 2008;48:236-247
38. Becker WJ. Zolmitriptan versus sumatriptan comparison trial. Headache 2001;41:321-323
39. Pascual J, Vega P, Diener HC, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia 2000;20(5):455-461
40. Steiner TJ, Diener HC, MacGregor EA, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003;23(10):942-952
41. Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007;115:34-40
42. Peterlin BL, Rapoport A. Clinical pharmacology of the serotonin receptor agonist zolmitriptan. Expert Opin Drug Metab Toxicol 2007;3(6):899-911
43. Dowson AJ, Charlesworth BR, Green J, et al. Zolmitriptan nasal spray exhibits good long term safety and tolerability in migraine: Results of the INDEX trial. Headache 2005;45:17-24
44. Loder E, Silberstein SD, Abu-Shakra S, et al. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: A randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004;44(2):120-130
45. Tuchman M, Abu-Shakra S, Silberstein SD, et al. Oral zolmitriptan exhibits high efficacy and low recurrence rates in the acute treatment of true menstrual migraine: Results of a randomized controlled trial. Headache 2003;43:512
46. Tuchman M, Abu-Shakra S, Silberstein SD, et al. Oral zolmitriptan is efficacious as acute therapy for pure menstrual migraine: Results of a second large prospective, multicenter, placebo-controlled trial. Neurology 2003;60(Suppl 1):A94
47. Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology 2010;75(5):463-473
48. Donald WL, Paul W, Andrew DH, Warren WW. Efficacy of Zolmitriptan Nasal Spray in Adolescent Migraine. Pediatrics 2007;120:390
49. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in school children. BMJ 1994;309:765-769
50. Winner P, Rothner AD, Putnam DG, et al. Demographic and migraine characteristics of adolescents with migraine: Glaxowellcome clinical trials database. Headache 2003;43:451-457
51. Schurks M. Genetics of migraine in the age of genome-wide association studies. J Headache Pain 2012;13(1):1-9
52. Ferrari A, Tiraferri I, Neri L, Sternieri E. Why pharmacokinetic differences among oral triptans have little clinical importance: A comment. J Headache Pain 2011;12(1):5-12